Vaccine Info

Ambirix Hepatitis Vaccine

Authored by
Last reviewed
February 25, 2022
Fact checked by
Robert Carlson, MD

Ambirix Vaccine Description - 2022

Ambirix contains inactivated (killed) hepatitis A virus and ‘surface antigen’ (proteins from the surface) parts of the hepatitis B virus as active substances.

These vaccines are used to protect against the same diseases, but Twinrix Adult is given as a three-dose schedule, whereas Ambirix is given as 2 injections 6 to 12 months apart.

Protection against hepatitis B infections may not be obtained until after the second dose.

Ambirix is a registered trademark of the GlaxoSmithKline Group of Companies.

Ambirix Vaccine Indication

Ambirix is indicated in non-immune children and adolescents from 1 year up to and including 15 years of age for protection against hepatitis A and hepatitis B infection.

Ambirix should be used only when there is a relatively low risk of hepatitis B infection during the vaccination course.

Ambirix Vaccine Dosage

It is recommended that Ambirix be administered in settings where completion of the two-dose vaccination course can be assured. A dose of 1.0 ml is recommended for subjects from 1 year up to and including 15 years of age.

The standard primary course of vaccination consists of two doses, the first administered at the selected date and the second between 6 and 12 months after the first dose.

The recommended schedule should be adhered to. Once initiated, the vaccination's primary course should be completed with the same vaccine.

Vaccine Schedules for 2022

The CDC issues vaccine guidelines each year.  This year's recommended immunization schedules can be found here.

Ambirix Vaccine Clinical Studies

Three main studies of Ambirix were carried out in a total of 615 children from one year of age. All of the children received two doses of Ambirix six months apart. Two of the studies compared Ambirix with other vaccines against hepatitis A and B. The main measure of effectiveness was the proportion of vaccinated children who developed protective levels of antibodies one month after the last injection.

An additional study in 208 children compared the vaccine’s effectiveness when a six-month or a 12-month interval was used between the two injections.

Clinical Trials

No clinical trials found